Press Releases

Date Title
2/21/23 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
2/17/23 Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
1/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/9/23 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
1/5/23 Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
1/3/23 Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/28/22 Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
11/23/22 Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
Displaying 51 - 60 of 813